Abstract
Background: Melanoma is one of the most deadly skin cancers in humanity, which imposes extensive costs on governments. Fortunately, the death rate has decreased despite the increasing incidence of melanoma. Various treatment methods, including surgery, chemotherapy, radiotherapy, targeted therapy, and the like, are used to treat this disease. However, despite recent advances in diagnosis and treatment, melanoma remains one of the leading causes of death in the world. One of the new treatment methods is based on microRNAs, one of which is miRNA 206. The aim of this study was to determine the effect of MIR-206 on Toll-like receptor 2 (TLR2) and TLR4 in the melanoma cell line (A-375).
Methods: The present in vitro study was performed on melanoma cancer cells in RPMI640 culture medium containing 10% fetal calf serum at 37 ° C and 5% CO2 . After counting and dividing the cells, the cells inside the plate were stimulated in over time with the MIR-206 protein. Incubation was performed. After 48 hours, the cells were collected, the total mRNA was extracted, and the expression levels of TLR2 and TLR4 were examined by real-time polymerase chain reaction.
Results: The results demonstrated that the expression of TLR2 and TLR4 IL6 decreased in the melanoma cell line (A-375) in exposure to MIR-206. The results also showed the expression of nuclear factor kappa B in the melanoma cell line.
Conclusion: The findings confirmed the role of MIR-206 as a tumor suppressor in melanoma cancer. These results suggest that MIR-206 may be a new treatment for melanoma in the near future. Accordingly, MIR-206 can be considered a potential target in the gene therapy of patients with melanoma cancer, and one of the advantages of MIR-206 gene therapy in melanoma cancer over chemotherapy is the reduction of cytotoxicity and its invasiveness.